Your browser is no longer supported. Please, upgrade your browser.
ANVS Annovis Bio, Inc. monthly Stock Chart
Annovis Bio, Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own20.10% Shs Outstand6.87M Perf Week5.42%
Market Cap37.11M Forward P/E- EPS next Y-1.10 Insider Trans0.00% Shs Float4.09M Perf Month11.79%
Income-4.00M PEG- EPS next Q-0.16 Inst Own11.90% Short Float0.97% Perf Quarter14.74%
Sales- P/S- EPS this Y-20.20% Inst Trans8.14% Short Ratio1.54 Perf Half Y21.71%
Book/sh1.33 P/B4.10 EPS next Y-100.00% ROA-49.20% Target Price- Perf Year-
Cash/sh1.29 P/C4.22 EPS next 5Y- ROE-76.40% 52W Range2.42 - 10.61 Perf YTD-43.17%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.63% Beta-
Dividend %- Quick Ratio33.50 Sales past 5Y- Gross Margin- 52W Low125.39% ATR0.36
Employees2 Current Ratio33.50 Sales Q/Q- Oper. Margin- RSI (14)57.13 Volatility6.92% 7.56%
OptionableNo Debt/Eq0.00 EPS Q/Q-241.60% Profit Margin- Rel Volume1.21 Prev Close5.85
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume25.76K Price5.45
Recom2.00 SMA209.32% SMA509.82% SMA20014.96% Volume31,296 Change-6.78%
Nov-26-20 07:55PM  
Nov-16-20 09:15AM  
Nov-12-20 06:45AM  
Nov-02-20 06:45AM  
Oct-29-20 06:45AM  
Oct-26-20 06:35AM  
Oct-22-20 06:45AM  
Oct-20-20 06:45AM  
Oct-15-20 06:45AM  
Oct-12-20 04:05PM  
Sep-29-20 06:45AM  
Sep-03-20 06:45AM  
Sep-01-20 06:45AM  
Aug-31-20 05:00PM  
Aug-25-20 08:00AM  
Aug-20-20 06:45AM  
Aug-05-20 09:00AM  
Jul-28-20 07:22AM  
Jul-20-20 06:45AM  
Jul-07-20 06:45AM  
Jun-16-20 06:45AM  
Jun-09-20 06:45AM  
Jun-03-20 09:00AM  
Jun-02-20 06:45AM  
Jun-01-20 06:45AM  
May-27-20 06:45AM  
May-01-20 06:00AM  
Apr-30-20 06:45AM  
Apr-29-20 06:09AM  
Apr-23-20 07:00AM  
Apr-13-20 05:30PM  
Mar-19-20 09:00AM  
Feb-27-20 06:45AM  
Feb-20-20 07:00AM  
Feb-13-20 11:40AM  
Jan-31-20 11:46AM  
Jan-28-20 11:31PM  
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.